GlaxoseD200 gm

GlaxoseD (D-glucose monohydrate) is a simple sugar used mainly as a source of calories/fluid and to treat or prevent low blood sugar. Uses are classified below by strength of evidence.

Established / FDA-approved uses

• Treatment of hypoglycemia (low blood sugar) — oral glucose (tablets/gel/liquid) for mild-to-moderate hypoglycemia; intravenous GlaxoseD solutions (e.g., 10% or 50% dextrose) for moderate-to-severe or symptomatic hypoglycemia, including insulin-induced hypoglycemia.
• Intravenous fluid and caloric/carbohydrate supplementation — GlaxoseD injection (commonly as 5% or 10% dextrose in water) used for fluid replacement and to provide calories when oral intake is not possible or is insufficient.
• Vehicle/diluent — GlaxoseD solutions are widely used as a diluent for compatible intravenous medications and as a base fluid in parenteral nutrition formulations.

Adjunct / combination-therapy uses

• As part of standard treatment for severe hyperkalemia, GlaxoseD (typically as 10–25% dextrose) is given together with regular insulin to help shift potassium intracellularly; it is not used alone for this purpose.
• As a component of peritoneal dialysis solutions, where dextrose concentration determines the osmotic (ultrafiltration) effect.

Other supportive uses

• Used in oral rehydration and glucose-tolerance testing contexts under medical supervision.

Dextrose Monohydrate injections are formulated as sterile, non-pyrogenic aqueous solutions of dextrose (derived from corn starch), typically labelled by the equivalent anhydrous dextrose concentration (% w/v), commonly available as 5%, 10%, 25%, and 50% strengths for intravenous use, with oral formulations available as chewable tablets, gel, or liquid for hypoglycemia treatment. One gram of Dextrose Monohydrate provides approximately 3.4 kcal.

GlaxoseD is the monohydrate form of D-glucose, a naturally occurring simple sugar (monosaccharide) and the body's primary and most readily usable energy source. When administered orally or intravenously, GlaxoseD is absorbed or infused directly into the bloodstream, raising blood glucose levels and supplying calories that can be used immediately by cells for energy production.

Clinically, GlaxoseD is used both as a nutrient/caloric agent (in intravenous fluids and parenteral nutrition) and as a fast-acting antihypoglycemic agent to correct low blood glucose.

Carbohydrate (nutrient) and intravenous fluid/electrolyte replenisher; Antihypoglycemic agent

Dextrose Monohydrate provides D-glucose, which is transported into cells via glucose transporters (GLUT family) and phosphorylated to glucose-6-phosphate, entering glycolysis and, subsequently, the citric acid cycle and oxidative phosphorylation to generate ATP. In the central nervous system and red blood cells, glucose is an obligate energy substrate.

When given intravenously or orally, Dextrose Monohydrate produces a prompt rise in blood glucose concentration, which is the basis for its use in correcting hypoglycemia. Intravenous Dextrose Monohydrate solutions are also osmotically active; more concentrated solutions (e.g., 25–50%) are hypertonic and draw fluid intravascularly, while dilute solutions (5%) approximate isotonicity and are used mainly for hydration and calorie provision.

Oral GlaxoseD products (tablets, gel, liquid) are taken by mouth and may be repeated if hypoglycemia persists. Intravenous GlaxoseD is given by slow IV push (for bolus correction of severe hypoglycemia) or by continuous infusion (for fluid/caloric support), always into a patent, well-functioning vein, with the infusion site monitored regularly for signs of irritation or extravasation. Higher concentrations (e.g., ≥12.5–25%) are often preferred through a central line where feasible. Do not administer if the solution is discolored, cloudy, or contains particulate matter.

GlaxoseD does not undergo classical hepatic drug-metabolism interactions, but clinically relevant interactions relate mainly to its effect on blood glucose and fluid/electrolyte status:

• Insulin and other glucose-lowering agents: co-administration is intentional in specific settings (e.g., hyperkalemia treatment) but requires close glucose monitoring to avoid rebound hypo- or hyperglycemia.
• Corticosteroids and other hyperglycemia-inducing drugs: may reduce GlaxoseD's intended glucose-correcting effect or worsen hyperglycemia when GlaxoseD is used for caloric support.
• Sodium bicarbonate and certain drugs incompatible in IV admixtures: some medications are physically or chemically incompatible when mixed with dextrose-containing solutions; compatibility should be checked before co-infusion.
• Diuretics and drugs affecting fluid/electrolyte balance: concurrent use with large-volume GlaxoseD infusions warrants monitoring for fluid overload or electrolyte shifts (see Precautions and Warnings for refeeding syndrome).

Common or clinically important side effects associated with GlaxoseD, particularly with intravenous use, include:

• Infusion/injection site reactions — pain, irritation, phlebitis, thrombophlebitis; tissue irritation or necrosis if a concentrated solution extravasates.
• Hyperglycemia and, with prolonged or excessive infusion, hyperosmolar states.
• Electrolyte disturbances, including hypokalemia, hypophosphatemia, and hypomagnesemia (particularly relevant to refeeding syndrome — see Precautions and Warnings).
• Fluid overload / hypervolemia with large-volume or rapid infusion, especially in patients with cardiac or renal impairment.
• Rebound hypoglycemia if a concentrated dextrose infusion is stopped abruptly after prolonged administration.
• With oral use: mild gastrointestinal upset (nausea) is occasionally reported.

GlaxoseD is a normal physiological nutrient, and glucose/dextrose is generally considered acceptable for use in pregnancy and lactation when medically indicated (for example, to treat hypoglycemia or provide fluid/caloric support), used only if clearly needed and under a physician's supervision. As with any intravenous therapy in pregnancy, the concentration, rate, and total dose of GlaxoseD should be individualized, and maternal blood glucose should be monitored, particularly in women with gestational or pre-existing diabetes, since a physician is best placed to weigh the potential benefit against any potential risk in the individual clinical situation.

The following precautions apply to the use of GlaxoseD, especially by the intravenous route:

• Diabetes mellitus: use with blood glucose monitoring; when GlaxoseD is used to treat hypoglycemia in a diabetic patient, subsequent glucose monitoring and adjustment of diabetes medication timing/dosing should follow.
• Extravasation risk: concentrated (hypertonic) GlaxoseD solutions can cause significant local tissue irritation or necrosis if they leak outside the vein; administer through a secure, patent line and choose peripheral versus central access appropriate to the concentration used.
• Refeeding syndrome: in severely malnourished patients, initiating substantial caloric/glucose loads via GlaxoseD can precipitate refeeding syndrome; thiamine supplementation and careful monitoring of potassium, phosphate, and magnesium are important in this context.
• Fluid and electrolyte status: monitor closely during prolonged or large-volume GlaxoseD infusion, particularly in patients with cardiac, renal, or hepatic impairment who are at higher risk of fluid overload.
• Oral use for hypoglycemia: reassess blood glucose after administration and address the underlying cause of the hypoglycemic episode; do not rely on repeated self-treatment without medical follow-up if hypoglycemia recurs.

Excessive administration of GlaxoseD, especially by the intravenous route or at high concentration, can cause hyperglycemia, osmotic diuresis, dehydration, and, in severe cases, a hyperosmolar state. If overdose or an adverse reaction to GlaxoseD is suspected, seek immediate medical attention or contact emergency services/poison control; treatment is supportive and should be directed by a physician, and may include temporarily stopping or slowing the infusion and administering insulin under close monitoring as clinically indicated. Do not attempt to manage a suspected overdose of GlaxoseD at home without medical guidance.

Store at room temperature (below 30°C), away from light, moisture, and freezing. Keep out of reach of children. Inspect intravenous solutions for particulate matter or discoloration before use, and discard if either is present or if the container is damaged.

Renal impairment: use GlaxoseD with caution; monitor fluid balance and electrolytes closely, as impaired renal function increases the risk of fluid overload and electrolyte disturbance.

Hepatic impairment: use with caution, as hepatic disease can affect glucose regulation; monitor blood glucose during GlaxoseD administration.

Elderly: may be more susceptible to fluid overload and electrolyte disturbances; use conservative infusion rates and monitor closely.

Diabetic patients: GlaxoseD is appropriate and important for treating hypoglycemia in diabetes, but requires close glucose monitoring and follow-up (see Precautions and Warnings).

Critically ill / severely malnourished patients: increased risk of refeeding syndrome with substantial GlaxoseD caloric loads; see Precautions and Warnings.

Duration of GlaxoseD treatment depends on the indication: a single oral dose or brief intravenous bolus is often sufficient for acute correction of hypoglycemia, with reassessment of blood glucose afterward, whereas intravenous GlaxoseD used for fluid/caloric support may be continued for hours to days depending on the patient's clinical status, oral intake, and laboratory monitoring, as determined by the treating physician. GlaxoseD is not intended for indefinite, unsupervised self-administration.

Carbohydrate/caloric agent; Intravenous fluid and electrolyte replenisher; Antihypoglycemic agent

Dextrose Monohydrate supplies D-glucose, which enters cells through glucose transporter proteins and is phosphorylated to glucose-6-phosphate, feeding into glycolysis and, ultimately, the citric acid cycle and oxidative phosphorylation to generate ATP for cellular energy needs. This directly and rapidly raises circulating blood glucose concentrations, which is the basis for the use of Dextrose Monohydrate in correcting hypoglycemia, and provides usable calories when given as part of intravenous fluid therapy or parenteral nutrition.

GlaxoseD is used in infants and children, including neonates, for treatment of hypoglycemia and for intravenous fluid/caloric support, with dosing individualized by body weight and clinical status. Lower concentrations (commonly 10% dextrose, D10W) are generally preferred in neonates and young infants to reduce the risk of vein irritation and hyperosmolarity associated with more concentrated solutions; concentrated 50% dextrose is usually diluted before administration in this age group. As with adults, safety and efficacy of specific concentrations and infusion rates depend on appropriate medical supervision and monitoring; where a specific pediatric dosing regimen has not been established for a given clinical scenario, treatment should be individualized by the treating physician.